囊性纤维化调节剂疗法可以逆转囊性支气管病变
Peter G Middleton1,2, Nicholas J Simmonds3,4
1CF Service, Department Respiratory & Sleep Medicine Westmead Hospital Sydney New South Wales Australia.
Respirology case reports
|June 16, 2023
概括
新的CFTR调节器疗法显示出在囊性纤维化患者中逆转肺损伤的潜力. 这项研究突出了支气管病变的可能回归,为改善长期结果提供了希望.
科学领域:
- 肺部病理学 肺部病理学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 支气管切除症通常被视为一种渐进且不可逆转的疾病.
- 囊性纤维化 (CF) 是一种遗传性疾病,由囊性纤维化跨膜导电性调节器 (CFTR) 基因的突变引起.
- CFTR调节器疗法改变了CF护理,显示了患者健康的快速改善.
研究的目的:
- 调查elexacaftor + tezacaftor + ivacaftor (ETI) 对CF成年人肺部结构异常的长期影响.
- 探索在接受长期ETI治疗的CF患者中逆转支气管切除症的潜力.
- 了解支气管切开症的维持和进展背后的机制.
主要方法:
- 使用了一种案例系列方法.
- 这项研究集中在三名患有囊性纤维化症的成年患者身上.
- 评估了elexacaftor + tezacaftor + ivacaftor (ETI) 治疗的长期结果.
主要成果:
- 三名成年CF患者在支气管切除中呈现逐渐改善.
- 观察到的改善包括减少圆柱形,静脉和囊性变化.
- 这些积极的结构变化发生在长时间的ETI治疗中.
结论:
- 长期使用elexacaftor + tezacaftor + ivacaftor (ETI) 的治疗可能会导致囊性纤维化患者的支气管切除症逆转.
- 这表明,CF中的结构性肺部异常可能比以前认为的更可逆.
- 需要进一步的研究来阐明与CF相关的支气管支气管病变逆转相关的机制.
相关概念视频
01:24Cystic Fibrosis: Management
199
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
199
01:23Cystic Fibrosis: Pathogenesis
301
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
301
01:26COPD: Management Using Bronchodilators and Corticosteroids
255
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
255
01:19Antiasthma Drugs: Leukotriene Modifiers
372
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
372
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
01:21Drugs for Treatment of Constipation-Predominant IBS
232
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
232